中国药物警戒 ›› 2025, Vol. 22 ›› Issue (4): 452-455.
DOI: 10.19803/j.1672-8629.20240461

• 安全与合理用药 • 上一篇    下一篇

拉考沙胺口服溶液致癫痫患儿药物性皮炎1例分析

罗雯1,2, 吴静3, 何大可3#, 杨锐1,*   

  1. 1上海交通大学医学院附属新华医院临床药学部,上海 200092;
    2四川省江油市人民医院临床药学科,四川 江油 621700;
    3上海交通大学医学院附属新华医院儿神经内科,上海 200092
  • 收稿日期:2024-07-05 发布日期:2025-04-17
  • 通讯作者: *杨锐,女,博士,主管药师,临床药学。E-mail: Lwen1129@163.com,#为共同通信作者。
  • 作者简介:罗雯,女,硕士,主管药师,临床药学。
  • 基金资助:
    上海市临床重点专科项目经费资助（shslczdzk06503）; 上海市“医苑新星”青年医学人才培养资助计划[SHWRS（2022）_65号]

One Case of Dermatitis Medicamentosa in a Paediatric Epilepsy Patient Caused by Lacosamide Oral Solution

LUO Wen1,2, WU Jing3, HE Dake3#, YANG Rui1,*   

  1. 1Department of Clinical Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;
    2Department of Clinical Pharmacy, Jangyou People’s Hospital, Jangyou Sichuan 621700, China;
    3Department of Pediatric Neurology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Received:2024-07-05 Published:2025-04-17

PDF (PC)

56

摘要： 目的 探讨拉考沙胺致药物性皮炎病例,为临床安全合理用药提供参考。方法 分析1例2岁男性癫痫患儿应用拉考沙胺口服溶液致药物性皮炎的病例,评估其药品不良反应发生的可能因素与用药安全性。结果 根据Naranjo不良反应因果关系评估量表,考虑拉考沙胺致药物性皮炎可能性大,停药并予以抗过敏治疗后,患者未再出现相关不良反应。结论 拉考沙胺可能会引起患者药物性皮炎的发生,使用时应注意给药剂量与血药浓度监测,以确保临床用药的安全性和有效性。

关键词: 拉考沙胺, 口服溶液, 儿童, 癫痫, 药物性皮炎, 药品不良反应, 安全性, 有效性

Abstract: Objective To analyze dermatitis medicamentosa caused by lacosamide oral solution so as to provide references for safe and rational drug use. Methods A retrospective study was conducted on a pediatric epilepsy patient who experienced dermatitis medicamentosa after oral administration of lacosamide oral solution. The potential cause of the adverse drug reaction and overall safety were explored. Results The Naranjo scale suggested that lacosamide was likely associated with the adverse drug reaction. Following discontinuation of lacosamide oral solution and symptomatic treatment, the symptoms of dermatitis medicamentosa disappeared gradually. Conclusion It is recommended that lacosamide be administered at a small dose that should be increased gradually in children under 4 years old. The blood concentration should be monitored to ensure the safety.

Key words: Lacosamide, Oral Solution, Children, Epilepsy, Dermatitis Medicamentosa, Adverse Drug Reaction, Safety, Efficacy

中图分类号: